Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 5758: Characteristic profile of blood-based ctDNA suggests angiogenesis and immune escape in hepatocellular carcinoma

View through CrossRef
Abstract Background: Circulating tumor DNA (ctDNA) is a type of DNA released from tumor cells captured in blood circulation system. It provides a noninvasive approach to interrogate a patient’s genomic landscape and actionable mutations with well application prospect. However, the difference of genomic profiles between tissue and ctDNA still brings confusions to related researches. Therefore, we tried to elucidate whether blood-based ctDNA has its own characteristic profile to reflect tumor status in hepatocellular carcinoma (HCC). Methods: Tumor tissue and blood samples from 118 HCC patients of Xiangya Hospital Central South University, were analyzed using NGS (panel on 147 gene). NGS data from a Chinese population extended cohort (385 tissues and 79 blood samples) of HCC were used to validate the mutation characteristics. Data from HCC cohorts of The Cancer Genome Atlas (TCGA) was used to analyze the disease-free survival (DFS) of different mutations. Results: In the hospital cohort, there were 9 high-frequency mutant genes in tissue and blood, including TP53 (74.58% vs 74.58%), MSH2(23.73% vs 8.47%), LRP1B (20.34% vs 23.73%), ATM (18.64% vs 13.56%), CTNNB1 (11.86% vs 13.56%) et.al which consistent with previous reports. There were 32 genes (74.04%) with a mutation frequency of more than 6% that were unique to blood samples. In extended cohort, the mutation profile was similar to the hospital cohort, in which 35 genes (52.24%) specific in ctDNA profile and 18 genes of them identical to the hospital cohort. Interestingly, when these ctDNA-specific genes were analysed by gene ontology, most genes were involved in angiogenesis. The prognostic analysis in ctDNA-specific genes showed that patients with higher level of MAP3K1 had worse DFS (p=0.028). In addition, the gene co-expression network analysis showed MAP3K1 and NOTCH1/2/3 expression had a significant positive correlation, that Notch family members were also belonged to the ctDNA-specific genes and associated with tumor immune escape. Conclusions: The results showed the mutation characteristic of tissues and ctDNA in HCC, and suggest that angiogenic and tumor immune escape related ctDNA-specific genes might be able to predict recurrence risk independently of baseline tissue samples. Citation Format: Lin Chia Yan, Liu Miao, Hu Xue, Huang Meng Li. Characteristic profile of blood-based ctDNA suggests angiogenesis and immune escape in hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5758.
American Association for Cancer Research (AACR)
Title: Abstract 5758: Characteristic profile of blood-based ctDNA suggests angiogenesis and immune escape in hepatocellular carcinoma
Description:
Abstract Background: Circulating tumor DNA (ctDNA) is a type of DNA released from tumor cells captured in blood circulation system.
It provides a noninvasive approach to interrogate a patient’s genomic landscape and actionable mutations with well application prospect.
However, the difference of genomic profiles between tissue and ctDNA still brings confusions to related researches.
Therefore, we tried to elucidate whether blood-based ctDNA has its own characteristic profile to reflect tumor status in hepatocellular carcinoma (HCC).
Methods: Tumor tissue and blood samples from 118 HCC patients of Xiangya Hospital Central South University, were analyzed using NGS (panel on 147 gene).
NGS data from a Chinese population extended cohort (385 tissues and 79 blood samples) of HCC were used to validate the mutation characteristics.
Data from HCC cohorts of The Cancer Genome Atlas (TCGA) was used to analyze the disease-free survival (DFS) of different mutations.
Results: In the hospital cohort, there were 9 high-frequency mutant genes in tissue and blood, including TP53 (74.
58% vs 74.
58%), MSH2(23.
73% vs 8.
47%), LRP1B (20.
34% vs 23.
73%), ATM (18.
64% vs 13.
56%), CTNNB1 (11.
86% vs 13.
56%) et.
al which consistent with previous reports.
There were 32 genes (74.
04%) with a mutation frequency of more than 6% that were unique to blood samples.
In extended cohort, the mutation profile was similar to the hospital cohort, in which 35 genes (52.
24%) specific in ctDNA profile and 18 genes of them identical to the hospital cohort.
Interestingly, when these ctDNA-specific genes were analysed by gene ontology, most genes were involved in angiogenesis.
The prognostic analysis in ctDNA-specific genes showed that patients with higher level of MAP3K1 had worse DFS (p=0.
028).
In addition, the gene co-expression network analysis showed MAP3K1 and NOTCH1/2/3 expression had a significant positive correlation, that Notch family members were also belonged to the ctDNA-specific genes and associated with tumor immune escape.
Conclusions: The results showed the mutation characteristic of tissues and ctDNA in HCC, and suggest that angiogenic and tumor immune escape related ctDNA-specific genes might be able to predict recurrence risk independently of baseline tissue samples.
Citation Format: Lin Chia Yan, Liu Miao, Hu Xue, Huang Meng Li.
Characteristic profile of blood-based ctDNA suggests angiogenesis and immune escape in hepatocellular carcinoma [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13.
Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5758.

Related Results

Longitudinal circulating tumor DNA kinetics and correlation with patient outcomes in metastatic melanoma.
Longitudinal circulating tumor DNA kinetics and correlation with patient outcomes in metastatic melanoma.
e21538 Background: Previous studies have shown circulating tumor DNA (ctDNA) to be an accurate noninvasive method for detecting minimal residual disease and predicting therapeutic...
Abstract P2-01-29: Prognostic value of circulating tumor DNA in metastatic breast cancer
Abstract P2-01-29: Prognostic value of circulating tumor DNA in metastatic breast cancer
Abstract Introduction: Circulating tumor DNA (ctDNA) is widely used in the management of metastatic breast cancer (MBC) for tumor genotyping and detection of actiona...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma
Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma
Introduction Circulating tumor DNA (ctDNA) which is tumor‐specific DNA sequences found in blood, has been considered an important new strategy that will aid in the t...
[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED]Guardian Blood Balance Reviews (Works Or Hoax) Does Guardian Botanicals Blood Balance AU Really Works? Read Updated Report! Diabetes and Hypertension is such a health p...
Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
Purpose. Melanoma is the most aggressive form of skin cancer. Circulating tumor DNA (ctDNA) is a diagnostic and prognostic marker of melanoma. However, whether ctDNA mutations can ...
The utility of ctDNA in colorectal cancer with peritoneal metastases
The utility of ctDNA in colorectal cancer with peritoneal metastases
AbstractBackgroundThe development of peritoneal metastases (PM) in patients with colorectal cancer (CRC) connotates a poor prognosis. Circulating tumour (ctDNA) is a promising tumo...

Back to Top